Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation recently completed a Phase 3 clinical ...

纽约 - 市值为1.19亿美元的临床阶段生物技术公司IO Biotech (NASDAQ: IOBT )将于周一美国东部时间上午8:30 (北京时间20:30)举行电话会议和网络直播，公布其关键性三期试验的初步结果。该试验研究Cylembio联合pembrolizumab用于晚期黑色素瘤治疗。该公司股票表现波动显著，过去一周下跌18%，而六个月内上涨近100%。 InvestingPro ...

在涉及407名不可切除或转移性黑色素瘤患者的关键第3期试验中，联合疗法实现的中位无进展生存期为19.4个月，而pembrolizumab单药治疗为11.0个月 (HR=0.77，p=0.056)。

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

This article highlights recent research on breast cancer, lung cancer, melanoma, head and neck cancer, and hematologic malignancies.

New trial results reveal enfortumab vedotin and pembrolizumab significantly improve survival for muscle-invasive bladder ...

All received pembrolizumab followed by a second cycle + RT (anti-PD1/RT) of 24 Gy/three daily fractions delivered to the breast tumor and then neoadjuvant chemotherapy (NAC). Blood and tumor biopsies ...

Pembrolizumab showed an 89% objective response rate in unresectable desmoplastic melanoma, with a 37% complete response rate.

Background: Relapse after surgery for high-risk clear cell RCC (ccRCC) is associated with shortened life expectancy. Effective perioperative therapy to reduce this risk remains an unmet need. Adjuvant ...

Pembrolizumab conferred a small but statistically significant survival benefit when added to best supportive care as second-line treatment for patients with advanced hepatocellular carcinoma ...